Dystonia is defined by involuntary maintained contraction of agonist and antagonist muscles yielding abnormal posturing, twisting and repetitive movements, or tremulous and can be initiated or worsened by attempted movement.
Dystonia is a dynamic disorder that changes in severity based on the activity and posture. Dystonia may assume a pattern of overextension or over-flexion of the hand, inversion of the foot, lateral flexion or retroflection of the head, torsion of the spine with arching and twisting of the back, forceful closure of the eyes, or a fixed grimace. It may come to an end when the body is in action and during sleep.
Dystonia may vary greatly in severity and may show obvious fluctuations in individual patients. Severe cases result in grotesque and distorted movements. The degree of severity is variable.
It is frequently unrecognized or misdiagnosed because of its variable course and abundant expression.
Usually, people with dystonia can live a relatively normal lifestyle, while others need assistance with all activities of daily living.
In primary dystonia (familial or sporadic, also called idiopathic torsion dystonia), dystonia is the sole neurologic sign (with exception of the tremor) and other causes of dystonia such as acquired or neurodegenerative processes have been ruled out.
Primary dystonia is further classified into early-onset and adult-onset forms.
Primary dystonia is thought to have a greater genetic contribution, even in the absence of a family history of dystonia. The precise cause of primary dystonia is unknown. There is some genetic susceptibility in conjunction with environmental factors.
Early-onset primary dystonia typically initially affects an extremity and then spreads, in many occurrences becoming generalized. DYT 1 and DYT 6 are the two genes that are responsible for early onset of primary dystonia.
As far as adult-onset dystonia usually involves either cervical, cranial, or brachial muscles, or remains focal or segmental. Worth mentioning that cervical dystonia is the most common form and at the same time is more common than early-onset primary dystonia.
Secondary dystonias are caused by the environmental insult and are brought in by some identified causes, such as head injury, drug side effects (e.g., tardive dyskinesia) or neurological disease (e.g., Wilson disease).
An intermediary category is termed ‘dystonia plus syndromes,’ and consists of disorders in which there is no acquired etiology or neurodegeneration, but in which there are neurologic symptoms other than dystonia. This category includes dopa-responsive dystonia (DRD/DYT5), myoclonus dystonia (MD/DYT11) and rapid-onset dystonia-parkinsonism (RDP/DYT12).
Medications associated with dystonia:
Dystonia is the third most prevalent movement disorder, affecting approximately 500,000 adults and children in North America.
After Parkinson, dystonia is the most common movement disorder encountered in movement disorder clinics.
The principal cause of dystonia has been thought to be dysfunction of the basal ganglia, which emerged from the concept of the basal ganglia as the brain region responsible for integrating motor control. Also, secondary dystonia is often due to lesions of the basal ganglia, specifically the putamen or globus pallidus.
However, the absence of neurodegeneration in primary dystonia, as well as observations that lesions of brain regions other than the basal ganglia can cause secondary dystonia, has guided to the idea that dystonia is a neuro-functional disorder, i.e. a disorder characterized by abnormal connectivity that may occur in a structurally normal-appearing brain.
Dystonia is considered to be a motor system disorder rather than a disease of a particular motor structure. Studies have provided evidence of dysfunction in almost every region of the central nervous system involved in motor control and sensorimotor integration, including cortex, brainstem, cerebellum, and spinal cord.
Although standard MRIs have not revealed structural pathology, diffusion tensor imaging (DTI) has shown subtle abnormalities in the sensorimotor circuitry of dystonia patients. In DYT 1 mutation carriers there is reduced functional anisotropy (FA) in a sub-gyral white matter of the primary sensorimotor cortex, pons and left superior cerebellar peduncle. Abnormal functional anisotropy has also been observed in the lentiform nucleus and the white matter adjacent to the nucleus in patients with focal dystonia.
Neurophysiological studies demonstrate a variety of changes consistent with abnormalities in inhibitory control, sensorimotor integration, and brain plasticity. The EMG in the dystonia show co-contraction of agonist and antagonist muscles with prolonged bursts and overflow to the muscles.
Dystonia is worsened by stress, fatigue, anxiety, or lack of sleep.
It is important to distinguish between idiopathic and symptomatic dystonia (due to another disease process).
Idiopathic dystonia may be inherited, often has an insidious onset, and may come into sight initially during the execution of a specific, repetitive, well-learned action. In contrast, symptomatic (secondary) dystonia occurs after a stroke, tumor, infection, hypoxia-ischemia, encephalitis, neurodegenerative disease (e.g., hepato-lenticular degeneration or Wilson's disease), and toxins.
The clinical examination in dystonia may exhibit involuntary writhing/twisting movements precipitated by specific voluntary movements, such as walking or writing. Focal task-specific limb dystonia can begin as painful hand cramping or involuntary wrist/finger spasms when writing, while torticollis presents as an uncontrollable head-turning when driving or watching television.
In its early stages, it may be viewed as an annoying mannerism or hysteria, and only later due to unremitted postural abnormality, lack of the typical psychological characteristics of hysteria, and becoming an apparent feature of the illness, the correct diagnosis is made.
Dystonic movements tend to be exacerbated by fatigue, stress, and emotional states; they tend to be suppressed with relaxation, hypnosis, and sleep.
A characteristic and almost unique feature of dystonic movements is that they can abate by tactile or proprioceptive sensory tricks (geste antagoniste). For example, patients with cervical dystonia (torticollis) often place a hand on the chin or side of the face to diminish nuchal contractions, and oro-lingual dystonia is often relieved by touching the lips or placing an object in the mouth. Lying down may reduce truncal dystonia; walking backward or running may reduce leg dystonia.
Some dystonic movements last several seconds/minutes but others can last for weeks/months. This can lead to permanent bone deformity, contractures and impairment in function.
In primary dystonia, clinical evaluation and genetic testing (DYT1 and DYT6) can guide to the correct diagnosis. The gene at the DYT1 locus has been determined to serve as a cause of the dystonia described by Oppenheim. In a vast majority of patients with DYT1 dystonia, symptoms begin in childhood or adolescence, and the mean age of onset is 13 years. Oppenheim dystonia affects most ethnic groups but is considerably wide spread in the Ashkenazi Jewish population.
Dystonia plus syndrome encompasses nondegenerative disorders in which parkinsonism dopa-responsive dystonia (DRD) and rapid-onset dystonia-parkinsonism (RDP) or Myoclonus-Dystonia (M-D) co-occur with dystonia. Dopa responsive dystonia predominantly starts between ages six and 16 but can arise at any age. When it begins in infants has the appearance of cerebral palsy. When it occurs in adults, it often manifests as pure parkinsonism, responding to levodopa with a benign course. Dopa responsive dystonia affects girls more often than boys, has a worldwide distribution and is not known to have a higher specific prevalence in any particular ethnic group. Mutations in the gene for GTP cyclohydrolase 1(GCH1) located at 14q22.1 are accountable for the greater number of dopa-responsive dystonia. Dopa responsive dystonia can be suspected if a young patient with dystonia responds greatly to a low dose of anticholinergics. On the other hand, the most effective agent is levodopa.
Clues suggestive of secondary dystonia emerge from the definition of the disorder that develops as a result of environmental factors that affect the brain, especially the basal ganglia. Spinal cord injury and peripheral injury can serve as a cause of dystonia as well. So the history of possible head trauma, encephalitis, toxin and drug exposure, perinatal anoxia, also the presence of neurologic abnormality independently from dystonia, for example, Parkinsonism, dementia, seizures, ocular symptoms, ataxia, neuropathy, spasticity with abnormal brain imaging will guide to the diagnosis of secondary dystonia.
Because many of the neurodegenerations are a result of genetic abnormalities, the term Heredodegenerative dystonia is applied to this category. Dystonia in Neurodegeneration is a prominent feature. MRI of the brain, ceruloplasmin level, slit-lamp exam, lysosomal screen, peripheral blood smear, nerve conduction studies, creatine kinase (CK) level, vitamin E are a few worth mentioning investigations.
Imaging studies may identify central lesions, hemorrhage or hypoxic damage.
The medications that are most potent in the treatment of dystonia include anticholinergics (trihexyphenidyl), GABA agonists (baclofen and benzodiazepines), and dopaminergic agents. The mechanism of action of these drugs is due to modifications in dopaminergic and cholinergic neurotransmission and reduced GABA-mediated inhibition in the dystonic central nervous system (CNS).
Trihexyphenidyl is the first-line medication for management of childhood-onset primary generalized or segmental dystonia.
Focal dystonia can be effectively treated with botulinum toxin injections. The toxin blocks the vesicular release of acetylcholine into the neuromuscular junction, generating temporary local chemo-denervation and muscle weakness, lessening the excessive activity of the affected dystonic muscles.
Botulinum toxin is the first-line treatment for cervical dystonia and blepharospasm and is also habitually used to treat laryngeal dystonia (spasmodic dysphonia), and focal limb dystonia. Apart from its direct peripheral effect of weakening affected muscles, botulinum toxin injections may also reduce afferent feedback from affected muscles, possibly normalizing the abnormal plastic changes in the CNS.
The drug-induced tardive dyskinesia requires specialized treatment.
Historically, dystonia patients were treated surgically with pallidotomy or thalamotomy. These lesional surgeries provided significant benefit to dystonia symptoms in some cases, but also frequently caused permanent, debilitating side effects, particularly dysarthria. Lesional surgeries have now been succeeded by deep brain stimulation (DBS), which resembles a lesional effect but is reversible and adjustable. In the past two decades, DBS has come to the leading edge as an important treatment option for patients with severe medically refractory primary dystonia. The currently established target in DBS for dystonia is the globus pallidus (GPI). DBS is thought to produce its clinical effect by inducing functional changes within the abnormal motor networks in dystonia and ultimately normalizing pathologically overactive motor activation responses. In opposition to the rapid effect of DBS that occurs in Parkinson disease or essential tremor, the effect of DBS is typically delayed in dystonia, often taking weeks to months, confirming with the concept of dystonia as a disorder of sensorimotor connectivity that compels time to restyle and adapt to changes along the entire motor circuit after DBS.
There is a distinct variability in response to DBS among dystonia patients, with some patients showing dramatic improvement whereas others benefit only modestly or not at all, and no single factor, including DYT1 gene status, has been found to be undeniably predictive of response. The question which patient with primary dystonia will have the best response to DBS remains open and requires further investigation.
Whether DBS should be considered as a treatment option for secondary dystonia is not entirely understood.
Physical therapy may help individuals with focal or segmental dystonic movements. Speech therapists can offer communication aids and provide techniques to relax the jaw.
Classification based on anatomy
Dystonia is a neuro-functional disorder distinguished by modifications at different levels and numerous elements alongside the sensorimotor circuit. Numerous causes can lead to these disruptions and lesions along different points in interconnected pathways can yield similar motor dysfunction. Although the basal ganglia is a crucial brain region, abnormalities exist in many other regions throughout the motor circuit. Ultimately, a full comprehension of the pathophysiology of dystonia would most probably guide to a more effective, logical and directed therapy.
Because of the numerous causes of dystonia, the condition is best managed by an interprofessional team that includes a neurologist, neurosurgeon, internist, pharmacist, primary care provider, therapists, and nurse practitioner. The primary treatment of dystonia is with medications and botulinum toxin. The pharmacist should educate the patient on the importance of medication compliance to control the symptoms. In addition, many patients may benefit from physical and occupational therapy. Speech therapy can retain methods to communicate and offer aids to help with speech. Some patients may require ambulatory devices.
However, treatment is often long term and the drugs also have numerous side effects. Surgery is no longer used to treat dystonia but DBS may be an option. Because dystonia is often life long, many patients develop anxiety and depression, hence a mental health nurse should be involved in the counseling of these patients. Finally, the social workers should be involved to ensure that the patient has adequate support and finances; so care is not neglected. Only through close collaboration between the team can the morbidity of dystonia be minimized.
|||Novaretti N,Cunha ALN,Bezerra TC,Pena Pereira MA,de Oliveira DS,Macruz Brito MMC,Pimentel AV,Brozinga TR,Foss MP,Tumas V, The Prevalence and Correlation of Non-motor Symptoms in Adult Patients with Idiopathic Focal or Segmental Dystonia. Tremor and other hyperkinetic movements (New York, N.Y.). 2019; [PubMed PMID: 30783550]|
|||Dekopov AV,Pashin DL,Tomski AA,Isaguljan ED,Salova EM,Kamchatnov PR, [Long-term results of chronic intrathecal baclofen treatment in patients with spasticity and secondary dystonia]. Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova. 2019; [PubMed PMID: 30778029]|
|||Vizcarra JA,Lopez-Castellanos JR,Dwivedi AK,Schmerler DA,Ries S,Espay AJ, OnabotulinumtoxinA and cognitive behavioral therapy in functional dystonia: A pilot randomized clinical trial. Parkinsonism [PubMed PMID: 30777651]|
|||Trompetto C,Currà A,Puce L,Mori L,Serrati C,Fattapposta F,Abbruzzese G,Marinelli L, Spastic dystonia in stroke subjects: prevalence and features of the neglected phenomenon of the upper motor neuron syndrome. Clinical neurophysiology : official journal of the International Federation of Clinical Neurophysiology. 2019 Feb 6; [PubMed PMID: 30776732]|
|||Rajan S,Kaas B,Moukheiber E, Movement Disorders Emergencies. Seminars in neurology. 2019 Feb; [PubMed PMID: 30743298]|
|||Graham D,Paget SP,Wimalasundera N, Current thinking in the health care management of children with cerebral palsy. The Medical journal of Australia. 2019 Feb; [PubMed PMID: 30739332]|
|||Conte A,Defazio G,Hallett M,Fabbrini G,Berardelli A, The role of sensory information in the pathophysiology of focal dystonias. Nature reviews. Neurology. 2019 Jan 30; [PubMed PMID: 30700825]|
|||Huegel M,Kenyon LK, Application of the Clinical Practice Guideline for Congenital Muscular Torticollis: A Case Report. Pediatric physical therapy : the official publication of the Section on Pediatrics of the American Physical Therapy Association. 2019 Jan; [PubMed PMID: 30557293]|
|||Ravindran K,Ganesh Kumar N,Englot DJ,Wilson TJ,Zuckerman SL, Deep Brain Stimulation Versus Peripheral Denervation for Cervical Dystonia: A Systematic Review and Meta-Analysis. World neurosurgery. 2019 Feb; [PubMed PMID: 30419402]|
|||Defazio G,Albanese A,Pellicciari R,Scaglione CL,Esposito M,Morgante F,Abbruzzese G,Bentivoglio AR,Bono F,Coletti Moja M,Fabbrini G,Girlanda P,Lopiano L,Pacchetti C,Romano M,Fadda L,Berardelli A, Expert recommendations for diagnosing cervical, oromandibular, and limb dystonia. Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology. 2019 Jan; [PubMed PMID: 30269178]|
|||Wolf ME,Blahak C,Saryyeva A,Schrader C,Krauss JK, Deep brain stimulation for dystonia-choreoathetosis in cerebral palsy: Pallidal versus thalamic stimulation. Parkinsonism [PubMed PMID: 30718219]|
|||Rodrigues FB,Duarte GS,Prescott D,Ferreira J,Costa J, Deep brain stimulation for dystonia. The Cochrane database of systematic reviews. 2019 Jan 10; [PubMed PMID: 30629283]|